NCT04088409

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 2 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.

Conditions

• Uveitis

Interventions

Type	Name	Description
DRUG	Baricitinib	Administered orally
DRUG	Adalimumab	Administered SC

Timeline

• Start date: 2019-10-16
• Primary completion: 2023-07-17
• Completion: 2028-07-01
• First posted: 2019-09-12
• Last updated: 2025-04-20
• Results posted: 2024-08-13

Locations

20 sites across 5 countries: France, Germany, Italy, Spain, United Kingdom

Regulatory

• FDA-regulated drug study